tbuckley/cabot-search huggingface dataset:
OP0178 Analysis of b-cells subsets in first degree relatives of patients with systemic lupus erythematosus
Authors: A. Ruiz Roman, A. Muñoz Jimenez, J.M. Lucena, M.A. Montes Cano, B. Sanchez Sanchez, N. Garrido Puñal, E. Blanco Alonso, R. Gil, J. Quijada Carrera, E. Rubio Romero, J. Povedano Gomez
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune, multiorgan disease characterised by periods of activity and remission. In lupus, one of the fields that has most helped his knowledge is the study of lymphocyte subpopulations through flow cytometry. Specifically, in the SLE some alterations have been detected at the level of B lymphocytes as the increase of B-cells subsets such as plasmablasts, plasma cells, transitional cells. There are no studies to date that have analysed the behaviour of B cells subsets in first -degree relatives of patients affected by lupus <h3>Objectives</h3> To analyse if there quantitative difference in the B-cells subsets of the first-degree relatives of SLE with respect to the control population (healthy) and the lupus population <h3>Methods</h3> Transversal descriptive study. We included 13 patients diagnosed with SLE according to the criteria of the American College of Rheumatology (ACR) with positivity for antinuclear antibodies (ANA) and anti-DNA, 34 first-degree relatives and 50 healthy controls between the months of May 2016 and March 2017. None of the subjects evaluated received treatment with rituximab or belimumab. We analysed B-cells subsets (negative double, naïve B-cells, unswitched memory B-cells, switched memory B-cells) in all the subjects included in our study. The 95% confidence intervals were obtained for both the means and the percentage difference. The level of statistical significance was established at p&lt;0.05. The data was analysed with IBM SPSS software Statistics 19 and EPIDAT 4.1. <h3>Results</h3> 47 subjects were analysed between relatives and patients, of which 33 (70.20%) were women. 13 subjects (27.70%) were diagnosed with lupus. 100% of those diagnosed with lupus were women. The mean (X) and confidence intervals (95% CI) for the different subgroups (healthy subjects, subjects diagnosed with SLE, relatives of the first degree) is shown in table 1. In none of the subpopulations analysed in patients diagnosed with SLE in front of relatives of 1 st grade it has reached statistical significance. When analysing B cells subsets of the three groups of subjects, we did find statistically significant differences between unswitched memory B cells of healthy subjects and 1 st degree relatives (being lower in the group of healthy subjects) This finding has not been described in any previous study, although it should be noted that the sample before us is small. <h3>Conclusions</h3> There are quantitative differences between unswitched memory B-cells of healthy subjects and relatives of 1 st grade of SLE. More studies with a larger sample size are necessary to see the behaviour of the rest of B-type lymphocyte subpopulations <h3>Disclosure of Interest</h3> None declared
SAT0170 Anti-il-6 therapy modulates leptin in patients with rheumatoid arthritis
Authors: R. López-Mejías, F. Genre, S. Remuzgo-Martínez, V. Mijares, J. Calvo-Alen, R. Blanco, J. Llorca, S. Castañeda, M. A. González-Gay
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Leptin is an adipocytokine that plays an important role in the regulation of body weight and also participates both in immune homeostasis and inflammatory processes [1,2]. Chronic systemic inflammation is of major importance in the development of atherosclerosis in rheumatoid arthritis (RA) [3]. IL-6 blocker yields a rapid improvement of endothelial function [4]. <h3>Objectives:</h3> To determine whether the infusion of IL-6 blockade improves the endothelial function by altering circulating Leptin concentrations in patients with RA. <h3>Methods:</h3> 50 Spanish patients on treatment with anti-IL-6 monoclonal antibody-Tocilizumab who fulfilled the 2010 classification criteria for RA [5] were recruited. Patients with diabetes mellitus or plasma glucose &gt;110 mg/dl were excluded. Leptin serum levels were determined immediately prior to (time 0) and after (time 60 minutes) Tocilizumab infusion by Enzyme-Linked ImmunoSorbent Assay (ELISA). <h3>Results:</h3> A significant reduction in Leptin concentration was observed following Tocilizumab infusion (mean±standard deviation (SD): 9.24±7.98 ng/ml <i>versus</i> 7.91±7.36 ng/ml, p&amp;x003C;0.0011). In addition, a significant positive correlation between Leptin concentration and insulin resistance (HOMA at the time of the study) was found (r= 0.40; p=0.0046). Furthermore, a significant negative correlation between Leptin levels and insulin sensitivity (QUICKI) was disclosed (r= -0.46; p=0.0009). <h3>Conclusions:</h3> Our study confirms that circulating Leptin concentrations are modulated by anti-IL-6 treatment. In addition, Leptin concentration correlates with insulin resistance and sensitivity. The beneficial effect of anti-IL-6 blockage on cardiovascular mortality in RA may be mediated by reduction in serum levels of leptin. <h3>References</h3> 1] Nat Rev Immunol2006;6:772–83. 2] Nat Rev Immunol2006;6:772–83. 3] Autoimmun Rev2016;15:1013–30. 4] Atherosclerosis2011;219:734–6. 5] Arthritis Rheum2010;62:2569–81. <h3>Acknowledgements:</h3> This study was supported by European Union FEDER funds and "Fondo de Investigación Sanitaria" (PI15/00525) from 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain). It was also partially supported by RETICS Program RD16/0012 (RIER) from the ISCIII, and in part by grants from the European IMI BTCure Program. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, "Investing in your future") (CP16/00033). FG is a recipient of a Sara Borrell post-doctoral fellowship from the ISCIII, co-funded by ESF (CD15/00095). SR-M is supported by funds of the RETICS Program (RIER) RD16/0012/0009 (ISCIII, co-funded by the European Regional Development Fund, ERDF). VM is supported by funds of a Miguel Servet type I programme (CP16/00033) (ISCIII, co-funded by ERDF). <h3>Disclosure of Interest:</h3> None declared
Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study
Authors: Andrei Shustov, Patrick B Johnston, Stefan Klaus Barta, Gajanan Bhat, Guru Reddy, Yasuhiro Oki
Journal: Blood (2017)
AB0109 Characterisation and comparison of serum biomarkers in patients with rheumatoid arthritis versus osteoarthritis using mass spectrometry
Authors: A. Circiumaru, C. Butnaru, M. Bojinca, S. Petrescu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There is increasing interest in biomarkers in medicine, especially for their use as a diagnostic tool and in disease outcome prognosis. Rheumatoid arthritis (RA) is a chronic autoimmune disease with important debilitating outcome potential, therefore a biomarker panel may improve early diagnosis meaning better therapeutic management and lower social costs. Recently, mass spectrometry has emerged as one of the leading methods to identify new biomarkers for different pathologies as well as being able to determine their potential interactors in their cellular pathway. <h3>Objectives</h3> To characterise biomarkers using mass spectrometry, from sera of patients with RA and make a comparison between RA, osteoarthritis (OA) and healthy controls. <h3>Methods</h3> Blood was collected from 26 subjects, 12 patients with RA, 12 patients with OA, and 2 HC, centrifuged and sera was collected in dedicated tubes. Sera were separated by SDS-Page electrophoresis and stained with Coomassie staining. The samples were subjected to in gel digestion followed by LC/MS analysis. The obtained spectra were searched with Proteome Discoverer v1.4 using SEQUEST algorithm. <h3>Results</h3> A total of 985 proteins were identified, from which 323 were specific to the RA study group and 159 were characteristic to the OA group. Prevalent peptides found in the RA group were EGF-containing fibulin-like extracellular matrix protein 2, isoform DeltaLf of lactotransferrin, BPI fold-containing family B member 1 and isoform 2 of BPI fold-containing family A member 1. In the OA study group there was a prevalence in homeobox protein TGIF1, major facilitator superfamily domain-containing protein 9, methyltransferase-like protein 23, a fragment of the salivary acidic proline-rich phosphoprotein, serine/threonine-protein phosphatase 4 regulatory subunit 1, zinc finger protein 229. <h3>Conclusions</h3> Our results show a prevalence of peptides linked to cell migration, proliferation and activation in the RA sera as compared to peptides related to cell turnover and tissue senescence observed in OA sera. We believe further mass spectrometry studies of biomarkers in larger cohorts to be a promising tool for diagnosis and outcome prognosis in RA. <h3>Disclosure of Interest</h3> None declared
Response to: ‘Can solid-phase assays replace immunofluorescence for ANA screening?’ by Bizzaro
Authors: David S Pisetsky, Diane M Spencer, Peter E Lipsky, Brad H Rovin
Journal: Annals of the Rheumatic Diseases (2019)

We would like to thank Dr Bizzaro for his commentary1 on our article2 on the variability of testing for antinuclear antibodies (ANA) by indirect immunofluorescence (IIF). Along with other letters that have been published in response to our article,3–9 Dr Bizzaro’s letter highlights the concerns about the IIF, its status as the ‘gold standard’ and the availability of other technologies (eg, solid phase assays) that …
Identification of a Novel CEBPE Enhancer Essential for Granulocytic Differentiation
Authors: Pavithra Shyamsunder, Mahalakshmi Shanmugasundaram, Anand Mayakonda, Weoi Woon Teoh, Lin Han, Mei Chee Lim, Melissa Fullwood, Omer An, Henry Yang, Shi Jizhong, Md.Zakhir Hossain, Vikas Madan, H. Phillip Koeffler
Journal: Blood (2018)
THU0129 Predictive value of cd19 serum levels for long term therapeutic response and utility as biomarker for optimisation, in rheumatoid arthritis patients treated with rituximab
Authors: S. Melchor, E. Rodríguez, J.L. Pablos, P.E. Carreira
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rituximab (RTX) is a chimeric monoclonal antibody directed against CD20 antigens in B lymphocytes (BL) surface, producing selective depletion of BL, without affecting mature plasmatic cells. Current guidelines recommend optimisation of biologic therapy once remission has achieved in rheumatoid arthritis (RA) patients. A serum biomarker able to predict what patients would maintain remission after optimisation in RTX treated RA patients is lacking. <h3>Objectives</h3> To analyse the predictive value of CD19 serum level prior to RTX infusion for the long term maintenance of therapeutic response, and it's utility as a biomarker for optimisation in RA patients treated with RTX. <h3>Methods</h3> all RA patients treated with RTX in our centre during 2016 and 2017 for at least 6 months, and with 12 months follow-up, were included. Demographic data, clinical data related to RA, including activity parameters (DAS28, HAQ, ESR, RCP), number of infections, optimisation and serum levels of lymphocytic subpopulations (CD19, CD3 and CD56) and immunoglobulins (Ig) prior to each RTX cycle were collected. Optimisation was defined as any dose decrease (lower dose for cycle and/or increase interval between cycles). Recurrent infections were defined as three or more infections in one year. Descriptive statistics, correlation between basal levels of CD19, CD3 or CD56, and activity parameters or Ig levels at 6 and 12 months, and association studies between lymphocyte subpopulations and optimisation or recurrent infections were performed. <h3>Results</h3> Thirty patients (25 females, 60±12 year) with RA (24 RF/aCCP +, 17±11 years from disease onset), treated with RTX during 52±40 months, with an accumulated dose of 13±10 g were included. At study inclusion, DAS28 was 3,77±1,65, HAQ was 1,28±0,78 and 22 had been optimised. CD19 levels were lower than 2% in 22 patients (79%), including 10 with undetectable levels. CD19 levels (cels/mm³) were lower in optimised patients (73 vs 14, p=,03), and were correlated with DAS28 at 6 months (r=0,5; p=,007) and 12 months (r=0,44; p=,03), and with ESR at 6 m (r=0,6; p=,002). CD19 levels did not correlate with IgG levels, and were not associated with recurrent infections. CD3 and CD56 levels did not show any relevant association or correlation. <h3>Conclusions</h3> In RA patients treated with RTX for more than 6 months, CD19 levels correlate with long term therapeutic response, being low or undetectable levels predictors of good outcome, without association with Ig levels or increased infections. Our results suggest that CD19 levels before every RTX cycle might be a useful biomarker to select candidate patients for optimisation with this therapy. <h3>Disclosure of Interest</h3> None declared
AB1398-HPR The effects of kinesiophobia on pain, fatigue severity, functional exercise capacity, functional status and quality of life in fibromyalgia
Authors: Ç Gülşen, A. GÜÇLÜ GÜNDÜZ, F. SÖKE, K. ÇEKİM, Y. AYDIN, D. AKÇALI
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Kinesiophobia play an important role in the development of chronic pain in Fibromyalgia (FM) patients. This condition lead to increase clinical symptoms and reduce quality of life. <h3>Objectives</h3> The aim of the study is to examine the effects of kinesiophobia on pain, fatigue, functional exercise capacity,functional status and quality of life in FM patients. <h3>Methods</h3> Twenty-one FM patients were evaluated. We used Tampa Scale of Kinesiophobia (TSK) for perception kinesiophobia, Visual Analogue Scale (VAS) for pain intensity, Fatigue Severity Scale (FSS) for fatigue, six-minute walk test (6MWT) for functional capacity, Fibromyalgia Impact Questionnaire (FIQ) for the functional status, and Short-Form Health Survey (SF-36) for quality of life. <h3>Results</h3> The results of this study, there was a strong correlation between TSK and VAS, FSS, physical and mental components of SF-36 (r=0.754, r=0.762, r=0.780, and r=0.843, respectively; p&lt;0.05). There was a moderate correlation between TSK and FIQ and 6MWT (r=0.695, r=0.510, respectively; p&lt;0.05). <h3>Conclusions</h3> The results of the present study indicate that kinesiphobia can adversely affect pain, fatigue, functional status and functional exercise capacity, which is result in impaired quality of life in FM. Further, it demonstrates kinesiophobia can be a clinically appropriate assessment to evaluate patients and to determine the effectiveness of treatments in FM. <h3>Disclosure of Interest</h3> None declared
AB0301 Serum pyridinoline is associated with radiographic joint erosions in rheumatoid arthritis
Authors: S. Rajalingham, A.M.M. Nor Hashimah, S.S. Shaharir, R. Sridharan, A. Abdul Wahab
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pyridinoline (Pyd) is a 3-hydroxypyridinium derivative which is an intermolecular cross-link compound of type I and II collagen.<sup>1</sup> It is a marker of bone resorption based on bone biopsy and radioisotope kinetics studies.<sup>2</sup>In rheumatoid arthritis (RA), destruction of bones may contribute to increased levels of serum Pyd. <h3>Objectives</h3> The purpose of this study was to compare the serum pyridinoline (Pyd) levels between RA patients and healthy controls and to determine the correlation of serum Pyd levels with radiographic joint erosions. <h3>Methods</h3> This was a monocentric, cross sectional, case-control study which was conducted from June 2016 to February 2017 at the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Serum samples were obtained from 48 patients with RA and 48 healthy controls. The enzyme-linked immunosorbent assay (ELISA) method was used for quantitative analysis of serum Pyd. Besides, all the RA patients were assessed for joint damage based on Modified Sharp Score (MSS), disease activity based on the disease activity score in 28-joints (DAS 28) and functional capacity based on Health Assessment Questionnaires Disability Index (HAQ-DI). <h3>Results</h3> The median serum Pyd levels was much higher among the RA patients (110.20 ng/mL [92.30–120.64]) compared to the controls (98.22 ng/mL [85.54–111.41]); p&lt;0.05. RA patients with erosive disease had significantly higher serum Pyd levels (p=0.024). There was a significant positive correlation between serum Pyd levels and joint erosion score (r=0.285, p=0.049). The serum Pyd levels had no demonstrable association with disease activity or functional capacity. Neither steroid nor biologic therapy influenced the levels of serum Pyd. <h3>Conclusions</h3> RA patients had significantly higher levels of serum Pyd compared to healthy controls. The serum Pyd levels had significant correlation with radiographic joint erosions which reflected disease damage. <h3>References</h3> [1] Nemoto R, Nakamura I, Nishijima Y, Shiobara K, Shimizu M, Takehara T, et al. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. Br J Urol. 1997;80:274–80. [2] Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum2000;43:1473–7. <h3>Acknowledgements</h3> The authors would like to thank the Research Committee of UKMMC for funding this research. <h3>Disclosure of Interest</h3> None declared
Physician, Heal Thyself
Authors: Neal J. Thomas
Journal: Annals of Internal Medicine (2019)

On Being a Doctor15 January 2019Physician, Heal ThyselfNeal J. Thomas, MD, MScNeal J. Thomas, MD, MScPenn State College of Medicine, Hershey, Pennsylvania (N.J.T.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-2032 Audio Reading - “Physician, Heal Thyself” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Physician, Heal Thyself," by N.J. Thomas. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail “The work will always be there.”“No person ever said on their deathbed, 'I wish I spent more time at work.'”“Work smarter, not harder.”I had heard these words used many times to tell colleagues that overworking was not the path to happiness. But to me, they were just words. There were patients to see, grants to write, papers to publish, students to teach, and administrative work to complete. There were not enough hours in a day.I had always tried to put my family first, not missing lacrosse games or swim meets or karate tournaments. I got home ... Author, Article, and Disclosure InformationAffiliations: Penn State College of Medicine, Hershey, Pennsylvania (N.J.T.)Corresponding Author: Neal J. Thomas, MD, MSc, 500 University Drive, MC H085, Hershey, PA 17033; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Physician, Heal Thyself” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Physician, Heal Thyself," by N.J. Thomas. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 January 2019Volume 170, Issue 2Page: 135KeywordsAmbulancesEmotionsExerciseMemoryNutritionObesityReperfusionResidencySurgeonsThorax ePublished: 15 January 2019 Issue Published: 15 January 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Benefits of improved air quality on ageing lungs: impacts of genetics and obesity
Authors: Anke Hüls, Dorothee Sugiri, Michael J. Abramson, Barbara Hoffmann, Holger Schwender, Katja Ickstadt, Ursula Krämer, Tamara Schikowski
Journal: European Respiratory Journal (2019)

The beneficial effect of improving air quality on lung function in the elderly remains unclear. We examined associations between decline in air pollutants and lung function, and effect modifications by genetics and body mass index (BMI), in elderly German women.Data were analysed from the prospective SALIA (Study on the influence of Air pollution on Lung function, Inflammation and Aging) study (n=601). Spirometry was conducted at baseline (1985-1994; age 55 years), in 2007-2010 and in 2012-2013. Air pollution concentrations at home addresses were determined for each time-point using land-use regression models. Global Lung Initiative 2012 z-scores were calculated. Weighted genetic risk scores (GRSs) were determined from lung function-related risk alleles and used to investigate interactions with improved air quality. Multiple linear mixed models were fitted.Air pollution levels decreased substantially during the study period. Reduction of air pollution was associated with an increase in z-scores for forced expiratory volume in 1 s (FEV1) and the FEV1/forced vital capacity ratio. For a decrease of 10 µg·m-3 in nitrogen dioxide (NO2), the z-score for FEV1 increased by 0.14 (95% CI 0.01-0.26). However, with an increasing number of lung function-related risk alleles, the benefit from improved air quality decreased (GRS×NO2 interaction: p=0.029). Interactions with BMI were not significant.Reduction of air pollution is associated with a relative improvement of lung function in elderly women, but also depends on their genetic make-up.
Can Anesthesia Influence Cancer Outcomes After Surgery?
Authors: Nicholas J. S. Perry, Donal Buggy, Daqing Ma
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal